Monday, October 17, 2022 2:34:37 PM
I think you’re mostly joking. As obviously there would have to be a catalyst first. I don’t expect to wake up tomorrow to the news of an RS with out any approvals, or a significant order being PAID for, not just placed. That would be a disaster in my opinion. And they know that. Which is why they haven’t done it.
Maybe they would make a huge bet if there was a big Monkey Pox or Covid outbreak. But that would be so risky. Not worth it when things appear to very slowly and unsteadily coming together and aligning for this company. It looks like cash will last long enough for MP, cancer, and Alzheimer’s testing to get approved. I didn’t list Tollovid because I only give it 50/50 odds. All three of those stars align and revenue will go up $10 million year one, then $10 a quarter as they get in a rhythm year 2. Then $10 million a month year 3. That will get us a SP of $5 the old fashion way. But I suspect they would absolutely get bought Q3 of year two for the equivalent of maybe $3 a share based on current SP.
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM